cyrilzakka/clinical-trials huggingface dataset:
Esophageal Food Impaction

This study is designed to obtain data on the safety and efficacy of oral nitroglycerin solution for the treatment of esophageal food impaction in patients presenting to the Emergency Department with presumed esophageal food impaction. The main hypothesis is to determine the success rate of oral nitroglycerin solution in relieving the food impaction by assessing the resolution of symptoms and the ability of the patient to swallow.

A piece of food stuck in the esophagus (the tube connecting the mouth to the stomach) is a relatively common occurrence, estimated at a rate of 13 episodes per 100,000 people per year, mostly men, and usually attributed to swallowed meat. The current standard of care for patients presenting to an Emergency Department with this problem includes a trial of medication, usually glucagon but sometimes a carbonated beverage, an injection of nitroglycerin, or benzodiazepines. The medical interventions mentioned above have not been shown to be significantly effective and have unwanted side effects; glucagon is known to cause nausea and vomiting and benzodiazepines can cause sedation and depressed breathing. If the medication fails to relieve the problem, the patient may require a procedure called endoscopy, where a video scope and retrieval tool are inserted into the esophagus to remove the piece of food. There is significant risk associated with endoscopy, including the risks of anesthesia as well as with the physical procedure itself. Endoscopy also results in a prolonged hospital stay due to the time required for the procedure, as well as from anesthesia recovery. The ideal treatment would be a safe, inexpensive, quickly effective medication without significant side effects that could be administered without sedation or extensive monitoring. Oral nitroglycerin solution might just be that intervention.

Eligibility Criteria:
Inclusion Criteria:

* Over the age of 18 years
* Presentation consistent with esophageal food impaction
* Ability to swallow a small volume of liquid.

Exclusion Criteria:

* Intractable vomiting
* Hemodynamic instability or SBP \<100 mmHg
* Concern for or evidence of significant airway compromise
* Concern for or evidence of esophageal perforation,
* Concern for or evidence of coronary ischemia
* Presentation \> 12 hours since onset.
Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia

A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).

The investigators will explore the relationship between changes in Cerebral Blood Flow (CBF) and ventilatory chemoreflexes i.e. Acute Ventilatory Response to Hypoxia (AHVR) and Acute Hypercapnic Ventilatory Response (HCVR) before, during and after sleep under normoxic conditions and sleep accompanied by isocapnic Intermittent Hypoxia (IH) among healthy human study participants.

A pharmacological intervention will be utilized to manipulate the CBF in a randomized order. The study participants will also be randomly assigned the order to sleep either under normoxia or IH exposure. The experiments will be separated from one another with an interval of sufficient drug and IH exposure washout period. The venous blood samples and urinary samples will be collected for the vascular biomarkers.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults
* 18 - 45 years of age
* Living in Calgary for the past one year
* Have no medical condition or should not be taking any blood pressure medications.
* The participant should not be lactose intolerant

Exclusion Criteria:

* Cerebrovascular, cardio-respiratory, renal and metabolic diseases
* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease
* Pregnancy, obese and sleep-disordered breathing
* Drug allergies to non-steroidal anti-inflammatories
* Currently smoking
Evaluation of Cardiovascular Health Outcomes Among Survivors

This study will test a 2-tiered tailored intervention and evaluation of cardiovascular health outcomes among survivors designed to inform childhood cancer survivors about their individual cardiac risk and follow-up recommendations and to provide motivational support for cardiovascular (CV) screening. This study will test if the addition of telephone motivational interviewing, tailored to behavioral constructs, is superior to the current standard of care in increasing survivors' CV screening.

* This study will test the hypothesis that at 1 year post-intervention, a significantly greater proportion of the advanced-practice nurse (APN) phone counseling group will have undergone cardiovascular screening, as compared to the standard care group. Cardiovascular (CV) screening will be defined, based on established CV screening recommendations, as completion of an imaging evaluation of left ventricular systolic function (i.e., echocardiogram, multiple uptake gated acquisition scan, or cardiac magnetic resonance imaging).
* This study will measure changes induced by the intervention in survivors' knowledge, motivation, fear, beliefs, affect, readiness for medical follow-up, and self-efficacy and these changes' potential mediating effects on CV screening.

  * This study will provide a cost analysis of the ECHOS intervention in terms of the cost of left ventricular systolic function imaging per additional survivor screened, an estimate of the cost of standard care per survivor screened, and the cost of screening and follow-up per survivor screened.

Eligibility Criteria:
Inclusion Criteria:

1. Childhood Cancer Survivor Study (CCSS) cohort participants
2. Age 25 years or older
3. No CV screening in previous 5 years
4. Received anthracycline chemotherapy and/or irradiation of the chest
5. Previous history of successful independent (non-surrogate) response to CCSS surveys (reading level for non-medical items is 4th-6th grade Flesch-Kincaid level).

Exclusion Criteria:

1. Being followed at an institution actively recruiting adults to a long-term follow-up program (ascertained in CCSS follow-up database)
2. Inability or unwillingness of research participant to give written informed consent.
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts At Tertiary Care Hospital in Karachi.

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Eligibility Criteria:
Inclusion Criteria:

1. Patients presenting with greater than or equal to two warts
2. Either gender.
3. Age 18 - 60 years. -

Exclusion Criteria:

1. Pregnant or lactating women.
2. Patient not giving informed consent.
3. Patient received any treatment in the last 3 months period.
4. Patient with acute illness and immuno-suppressive disease.
5. Patient taking immuno-suppressive drugs.
6. Patient having hypersensitivity to any investigational medicine.
7. Patient having cutaneous warts on face and genitals.
8. Patient having cardiovascular disease.
9. Patient having renal disease. -
The Effect of Remote Ischemic Preconditioning Applied in Children the Day Before Open Heart Surgery

The study research is to analyse brief episodes of limb ischemia applied to children the day before open heart surgery as protection from myocardial injury induced by extracorporeal circulation.

Children undergoing repair of congenital heart defects were randomized to RIPC (remote ischemic preconditioning) or control treatment. RIPC was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff. Measurements of troponin I, brain natriuretic peptide, interleukines 8 and 10, real time PCR to NFKB and clinical parameters were obtained and compared postoperatively (4, 12, 24 and 48 hous after).

Eligibility Criteria:
Inclusion Criteria:

* 1 month to 2 years age
* waiting for open heart surgery in hospital
* 2008, january to march
* Rachs-1, except the 1 category

Exclusion Criteria:

* genetic syndromes
* infected children
* immunodeficiency
* immunosuppressor use
* no parents permission
Slow Expiratory Technique to Improve Alimentation in Children With Bronchiolitis

The purpose of this study is to determine wether a single chest physiotherapy session with slow expiratory technique (SET) improves infants with viral bronchiolitis quality of life (food intake and sleep) on the next 24 hours.

Bronchiolitis is the most common lower respiratory viral infection in infants. Nowadays bronchiolitis is the first reason of children hospitalisation worldwide. Symptoms are based on airway inflammation associated to an increased mucus production and cell necrosis leading to a multifactorial airway obstruction. Recommended treatments are supportive care based on oxygenation and rehydration. Airway clearance techniques represented by chest physiotherapy remain controversial.

Considering that bronchiolitis impacts respiratory condition in young infants feeding and sleep may be reduced. Evaluating quality of life represented by feeding and sleep in hospitalized infants may be an important outcome in this population.

The investigators hypothesized that chest physiotherapy with SET will improve children's quality of life, especially 24 hours food intake and sleep.

Eligibility Criteria:
Inclusion Criteria:

* children under 12 months
* hospitalized for bronchiolitis
* chest physiotherapy prescription
* bronchial obstruction confirmed by physician and respiratory physiotherapist

Non-inclusion Criteria :

* children more than 1 year
* exclusive breastfeeding or enteral feeding
* prematurity (gestational age \< 35 weeks)
* cardiac, neurological and pulmonary comorbidity
* continuous oxygen supplementation or ventilatory support
* chest physiotherapy contraindications

Exclusion Criteria:

* side effects during chest physiotherapy : bradycardia \<100 bpm, oxygen saturation\<90%, general state alteration
* outing, oxygen supplementation or parenteral nutrition less than 24 hours after randomization
* chest physiotherapy cessation according to family request
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study

Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study

This is a chart review.

Eligibility Criteria:
Inclusion Criteria:

* Patients with Ovarian Germ Cell Tumors in the last 27 years.
Implementation Strategy for a Peer-based Intervention to Prevent Teen Pregnancy

Previously studied peer-based educational videos on LARC (long-acting reversible contraceptive) devices will be incorporated into a high school health curriculum. This will then be administered to the intervention high school. Outcomes including LARC knowledge, attitudes and uptake will be compared to a control high school.


Eligibility Criteria:
Inclusion Criteria:

female, never used LARC, attending high school, less than 20 yo

Exclusion Criteria:

used LARC
Evaluation of Tangible Boost Replenishing System

This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating improves lens wettability, a common cause of patient discomfort. Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.


Eligibility Criteria:
Inclusion Criteria:

* Habitual contact lens wear with a group 3 FDA approved rigid lens material, with 20-50% of subjects wearing corneal lenses
* Willing and able to sign the informed consent form
* 18 years or older

Exclusion Criteria:

* Eye injury or surgery within the 3 months immediately prior to enrollment for this trial
* Pre-existing ocular irritation that would preclude contact lens fitting
* Current enrollment in an ophthalmic clinical trial
* Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of the accessory solutions, as determined by the investigator
* Any use of medications for which contact lens wear could be contraindicated, as determined by the investigator
* Pregnant women and nursing mothers
* Visual acuity less than 20/20 when best corrected with contact lenses
Effects of a Gum Gel Intended to Treat Signs and Symptoms of Teething

Teething discomfort is a widespread disorder affecting a very high percentage of infants. The use of hyaluronic acid gels has been shown in the last 20 years to be an effective tool, generally devoid of side effects, in reducing oral mucosal inflammation in adults. Its effectiveness in infants is affected by the strength of hyaluronic acid retention over the oral mucosa. This is in turn affected by formulation and may vary between different products due to the different ingredients used. In this study, the results collected by monitoring the paediatric experience regarding a newly developed HA-based medical device, intended to counteract teething discomfort in infants, will be reported.


Eligibility Criteria:
Inclusion Criteria:

* Teething discomfort
* Being healthy (except for teething discomfort)

Exclusion Criteria:

* Being placed on one of the following therapies in the 45 days prior to the beginning of the study: immunosuppressive, cytotoxic, cortisone, antibiotics, antifungal and hormone therapy
Time Restricted Feeding on Weight Loss and Cardio-protection (TREATY Trial)

Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. This is a randomized controlled trial to evaluate the effect of time restricted feeding (TRF) on weight loss and cardiometabolic risk factors in obese adults over 12 months compared to continuous energy restriction (CER).


Eligibility Criteria:
Inclusion Criteria:

1. Male of female aged between 18 and 75 years old;
2. Body mass index (BMI)of 28.0 to 45.0 kg/m2;

Exclusion Criteria:

1. History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis;
2. Diagnosis of type 1 and type 2 diabetes;
3. History of malignant tumors;
4. Serious liver dysfunction or chronic kidney disease (AST or ALT \> 3 times the upper limit of normal, or eGFR\<30 ml/min/1.73 m2);
5. History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months;
6. History of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months;
7. History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity;
8. Being a smoker or having been a smoker in the 3 months prior to their screening visit;
9. Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician;
10. Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ;
11. Women who are pregnant or plan to become pregnant;
12. Patients who cannot be followed for 24 months (due to a health situation or migration);
13. Patients who are unwilling or unable to give informed consent.
Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.

Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study procedures. This open-label extension study will consist of 44 weeks of treatment followed by a 2 weeks post-treatment follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Completed the 8-week double-blind treatment period of study LYC-30937-2001
* Male and females of childbearing potential must agree to use adequate birth control during the study and for 30 days after discontinuing study drug
* Non-pregnant, non-lactating females who are not planning to become pregnant while enrolled in this study
* Investigator considers it safe and potentially beneficial to participate
* Ability to provide written informed consent and to be compliant with study schedule

Exclusion Criteria:

* Subjects who completed study LYC-30937-2001, but who experienced a serious adverse event that was considered related to investigational product, has an unstable medical condition, or for any other reason in the opinion of the investigator should not participate in this study
The Effect of Draping on Swelling in Shoulder Arthroscopy

Strategies to minimize soft tissue swelling during shoulder arthroscopy are constantly sought after. The investigators propose an unfamiliar method which may reduce tissue swelling during shoulder arthroscopy.

Fluid extravasation into the surrounding tissue is common in shoulder arthroscopy. It frequently leads to soft tissue swelling and edema which results in poor visualization and prolonged surgical time. While usually resolves uneventfully within 12 hours, excessive fluid extravasation into the soft tissue around the shoulder may lead to serious consequences and complications such as airway compromise, tracheal deviation, neuropraxias, habdomyoloysis and skin necrosis have been reported in the literature. Methods aimed at reducing soft tissue swelling during shoulder arthroscopy in order to avoid complications (e.g., low pump pressure, short arthroscopic time) are routinely practiced. Nevertheless, fluid extravasation and soft tissue swelling remains a concern in shoulder arthroscopy.

The purpose of the current study is to evaluate whether applying local compression to the shoulder by preoperative compressive draping will reduce soft tissue swelling during shoulder arthroscopy. To the investigators' knowledge, no previous study evaluated the influence of applying compressive draping to the shoulder on soft tissue swelling in shoulder arthroscopy.

Eligibility Criteria:
Inclusion criteria for the study are defined as:

1. Surgery indicated for chronic symptomatic RC tear unresponsive to non-operative treatment over a minimal period of 6 months.
2. Small to medium size tears (\<3 cm).
3. Age older than 18 years.
4. ASA score 1or 2.
5. Body mass index (BMI) \< 35.
6. Willingness to provide an informed consent.

Exclusion criteria:

1. Pregnant women.
2. Arthroscopic procedure that was converted to an open ("mini-open") surgery.
3. Patients who do not meet the above mentioned inclusion criteria.
Decision Variability Between Different Heart Teams for Complex Coronary Artery Diseases

The purposes of this study are 1) to explore the variability of decisions between different heart teams in complex coronary artery disease; 2) to evaluate the reasons of the discrepancy in decision making.

Heart team has been recommended by guideline for optimizing the decision making for patients with complex coronary artery diseases (CAD). However, prior studies have demonstrated that heart team decision might have poor reproducibility, and the variability of heart team decision remains unknown.

Thus, the investigators designed a single-center, retrospective, cross-sectional study to explore the decision variability of heart team in CAD patients. The investigators will retrospectively recruit patients with angiographically confirmed 3-vessel or left main disease from a coronary angiography database at Fuwai hospital. Patients' baseline information will be collected. And different heart teams will be established and made decisions for the enrolled patients. First, the investigators will assess the decision variability between different heart teams. Secondary, the investigators will evaluate the reason of discrepancy by qualitative and quantitative analysis.

Eligibility Criteria:
Inclusion Criteria:

* Patients with angiographically confirmed 3-vessel disease or left main disease

Exclusion Criteria:

* Prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
* Myocardial infarction with acute phase judged by Electrocardiograph or biomarkers
* Combined with severe valvular disease, great vessel disease or huge ventricular aneurysm which need surgery
* Combined with atrial fibrillation or severe arrhythmia
The Efficacy of Tendoactive, Eccentric Training, and the Combination of Both as a Treatment of Achilles Tendinopathy

The purpose of this study is to determine whether Tendoactive, eccentric training, or the combination or both could be effective in the treatment of Achilles tendinopathy.


Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from a gradually evolving painful condition in the Achilles tendon located at the midportion for at least 3 months (Diagnosis based on clinical examination showing a painful thickening of the Achilles tendon located at a level of 2 to 6cm above the tendon insertion, and confirmed by ultrasonography: local thickening of the tendon, irregular tendon structure with hypoechoic areas and irregular fiber orientation).
* Men and non-pregnant women aged 18-70 years
* Be informed of the nature of the study and provide written informed consent.

Exclusion Criteria:

* Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)
* Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpable "gap")
* Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)
* Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)
* Clinical suspicion of peroneal subluxation
* Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
* Condition that prevents the patients from executing an active exercise programme
* Patient has already performed eccentric exercises, according to the schedule of Alfredson et al (12 weeks)
* Patient has already received an injection of PRP for this injury
* Patient does not wish, for whatever reason, to undergo one of the two treatments
* Known presence of a pregnancy
* Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins